News

  1. Positive Phase III Data On Bayer's Investigational Drug Alpharadin Show Significant Increase In Overall Survival 10/4/2011
    Bayer HealthCare Pharmaceuticals recently announced positive data on its investigational drug Alpharadin (radium-223 chloride) from the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.
  2. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis 9/21/2011
    Novartis announced recently positive results of the first pivotal Phase III trial of ACZ885 (canakinumab) in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease.
  3. GE Healthcare Launches Capto Blue Affinity Chromatography Medium 8/25/2011
    GE Healthcare’s Capto Blue affinity chromatography medium is for the capture of human serum albumin (HSA), as well as purification of HSA fusion proteins, blood coagulation factors, enzymes, and recombinant proteins at laboratory and process scales.
  4. XOMA Reports Second Quarter 2011 Financial Results 8/8/2011
    XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the second quarter and six months ended June 30, 2011 and provided a general business update.
  5. Genethon And Children's Hospital Boston Get FDA Approval For A Wiskott Aldrich Gene Therapy Trial 7/22/2011
    The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical research performed at Genethon (Evry, France) which also manufactures the GMP gene therapy product, is now going to be launched in Boston.
  6. FDA Approves Xarelto To Reduce Risk Of Blood Clots After Hip, Knee Replacements 7/8/2011
    On July 1, the U.S. Food and Drug Administration approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following knee or hip replacement surgery.
  7. Investment In Oncology Drug Development Remains Strong As 133 Companies Initiate Late-Stage Clinical Trials Representing A 21% Increase 6/6/2011
    Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development.
  8. Pharmacyclics Reports Recent Developments From Clinical Studies Of Its Btk Inhibitor PCI-32765 6/6/2011
    Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL) at the 2011 American Society of Clinical Oncology Annual Meeting.
  9. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells As Potential Biomarker For Metastatic Prostate Cancer Clinical Trials 6/4/2011
    Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials.
  10. NIH Stops Clinical Trial On Combination Cholesterol Treatment 5/27/2011
    The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned.